Replies to post #79 on Equity Field Notes from temporal sources

[DanWebzster]

FIXX is a recent early stage, gene therapy IPO

Lead product is a pre-Ph1 therapy for PKU

As of 12/31/17, net cash was $90mn. Gross proceeds from IPO was ~$100mn.

NVS is a partner and investor